Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 82, Issue 2, 2018, Pages 339-351

  Weekes, Colin D ^a   Rosen, Lee S ^b   Capasso, Anna ^c   Wong, Kit Man ^d   Ye, Weilan ^e   Anderson, Maria ^e   McCall, Bruce ^e   Fredrickson, Jill ^e   Wakshull, Eric ^e   Eppler, Steve ^e   Shon Nguyen, Quyen ^e   Desai, Rupal ^e   Huseni, Mahrukh ^e   Hegde, Priti S ^e   Pourmohamad, Tony ^e   Rhee, Ina ^e   Bessudo, Alberto ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e GENENTECH INC   (United States)

^f Department of Medical Oncology Hematology California Cancer Associates for Research and Excellence   (United States)

Author keywords

Angiogenesis; MINT1526A; VEGF; 5 1

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY; BEVACIZUMAB; MINT 1526A; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VERY LATE ACTIVATION ANTIGEN 5; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CAUSALITY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; COMBINATION DRUG THERAPY; CONSTIPATION; DEATH; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG INTOXICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRACELLULAR MATRIX; FATIGUE; FEMALE; FEVER; FIRST IN HUMAN STUDY; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART INFARCTION; HERNIA; HUMAN; HYPERTENSION; HYPESTHESIA; INFLUENZA; LIVER CELL CARCINOMA; LOWER ABDOMINAL PAIN; LUNG CARCINOMA; LUNG EMBOLISM; MALE; MAXIMUM CONCENTRATION; MAXIMUM TOLERATED DOSE; MINIMUM CONCENTRATION; MONOCYTE; MONOTHERAPY; MUSCLE SPASM; NAUSEA; NAUSEA AND VOMITING; OPEN STUDY; OVARY CANCER; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; PRURITUS; RASH; RECEPTOR OCCUPANCY; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SOLID MALIGNANT NEOPLASM; STOMA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR IMMUNOGENICITY; ULCER; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; MIDDLE AGED; NEOPLASM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTEGRIN ALPHA5BETA1; MALE; MIDDLE AGED; NEOPLASMS;

EID: 85048524302     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-018-3622-8     Document Type: Article

References (24)

1. Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156(4):1345–1362
2. Boudreau NJ, Varner JA (2004) The homeobox transcription factor Hox D3 promotes integrin α5β1 expression and function during angiogenesis. J Biol Chem 279(6):4862–4868. 10.1074/jbc.M305190200
3. Muether PS, Dell S, Kociok N, Zahn G, Stragies R, Vossmeyer D, Joussen AM (2007) The role of integrin alpha5beta1 in the regulation of corneal neovascularization. Exp Eye Res 85(3):356–365. 10.1016/j.exer.2007.06.004
4. Kim S, Bakre M, Yin H, Varner JA (2002) Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 110(7):933–941. 10.1172/jci14268
5. Silva R, D’Amico G, Hodivala-Dilke KM, Reynolds LE (2008) Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 28(10):1703–1713. 10.1161/atvbaha.108.172015
6. Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69(1):11–25
7. Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8(9):918–921. 10.1038/nm0902-918
8. Taverna D, Hynes RO (2001) Reduced blood vessel formation and tumor growth in alpha5-integrin-negative teratocarcinomas and embryoid bodies. Cancer Res 61(13):5255–5261
9. Vitorino P, Yeung S, Crow A, Bakke J, Smyczek T, West K, McNamara E, Eastham-Anderson J, Gould S, Harris SF, Ndubaku C, Ye W (2015) MAP4K4 regulates integrin-FERM binding to control endothelial cell motility. Nature 519(7544):425–430. 10.1038/nature14323
10. Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101(10):708–720. 10.1093/jnci/djp079
11. Garcia-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H (2017) Randomized phase II trial of parsatuzumab (anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer. Oncologist 22(4):375-e330. 10.1634/theoncologist.2016-0133
12. Fredrickson J, Serkova NJ, Wyatt SK, Carano RA, Pirzkall A, Rhee I, Rosen LS, Bessudo A, Weekes C, de Crespigny A (2017) Clinical translation of ferumoxytol-based vessel size imaging (VSI): feasibility in a phase I oncology clinical trial population. Magn Reson Med 77(2):814–825. 10.1002/mrm.26167
13. Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM (2010) Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol 194(2):W134–140. 10.2214/ajr.09.3116
14. Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, Tam RN, Clermont AC, Cheng JH, Yang SX, Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh RF, Yue P, Stephan JP, Hegde P, Ferrara N, Singh M, Bais C (2013) Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 19(13):3681–3692. 10.1158/1078-0432.ccr-12-3635
15. O’Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC (2012) Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 9(3):167–177. 10.1038/nrclinonc.2012.2
16. Ye W (2016) The complexity of translating anti-angiogenesis therapy from basic science to the clinic. Dev Cell 37(2):114–125. 10.1016/j.devcel.2016.03.015
17. Moreno Garcia V, Basu B, Molife LR, Kaye SB (2012) Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 18(14):3750–3761. 10.1158/1078-0432.ccr-11-1275
18. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R (2009) A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 15(19):6277–6283. 10.1158/1078-0432.ccr-09-0717
19. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. 10.1056/NEJMoa1303989
20. Negrier S, Perol D, Bahleda R, Hollebecque A, Chatelut E, Boyle H, Cassier P, Metzger S, Blanc E, Soria JC, Escudier B (2017) Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. BMC Cancer 17(1):547. 10.1186/s12885-017-3527-7
21. Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, Weiss G, Yazji S, Ng C, Wilding G (2008) Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 14(23):7924–7929. 10.1158/1078-0432.ccr-08-0378
22. Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H (2014) A first-in-human study of the anti-alpha5beta1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol 74(5):1039–1046. 10.1007/s00280-014-2576-8
23. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. 10.1056/NEJMoa0708857
24. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56–66. 10.1016/s0140-6736(16)32453-9